Provided by Tiger Trade Technology Pte. Ltd.

iShares Mortgage Real Estate ETF

20.79
-0.0900-0.43%
Post-market: 20.790.00000.00%19:30 EDT
Volume:431.11K
Turnover:8.99M
Market Cap:516.63M
PE:- -
High:21.08
Open:21.03
Low:20.77
Close:20.88
52wk High:24.05
52wk Low:20.41
Shares:24.85M
Float Shares:24.85M
Volume Ratio:1.28
T/O Rate:1.73%
Dividend:1.94
Dividend Rate:9.32%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

RemSense expands Woodside virtualplant deployments to ten assets

TIPRANKS
·
Sep 08

CELSYS Hits Record Subscription ARR and Revamps Disclosure Schedule

TIPRANKS
·
Sep 07

Morgan Stanley Private Meeting: MiniMax and Z.AI Show Accelerating ARR Growth as Model Competition Enters a Tiered Elimination Phase

Stock News
·
Sep 06

DocuSign: Upmarket Momentum and Raised FY27 ARR Outlook Support Hold as Risk-Reward Stays Balanced

TIPRANKS
·
Sep 04

RemSense Issues 25 Million Unquoted Options in Capital Management Move

TIPRANKS
·
Sep 04

ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study

TIPRANKS
·
Sep 04

Rithm Capital Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 03

Press Release: Netskope Announces Strong Second Quarter Fiscal 2027 Financial Results

Dow Jones
·
Sep 03

Palo Alto Networks Closes Record Fiscal Year Beating Guidance Across All Metrics With AI Security Recurring Revenue Surging 63% and Agent Traffic Ballooning Ninefold in Nine Months

Stock News
·
Sep 02

Starwood Property Trust Releases Transcript of Q2 2026 Earnings Call

Reuters
·
Sep 02

Rithm Capital Corp. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 02

AGNC Investment Corp. put volume heavy and directionally bearish

TIPRANKS
·
Sep 02

Meta-Butler deal officially scrapped, founding team reclaims control

Deep News
·
Sep 01

RemSense Issues New Shares Under Corporations Act Disclosure Exemption

TIPRANKS
·
Sep 01

RemSense seeks ASX quotation for additional ordinary shares

TIPRANKS
·
Sep 01

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

GlobeNewswire
·
Sep 01

Z.AI Sets Year-End Revenue Target of $2.4 Billion, Acknowledges 17-Month Gap to Rival, and Reports 40-Fold Surge in Token Usage After 101% Price Hike

Deep News
·
Sep 01

OpenAI’s Ad Business Smashes $1 Billion Revenue Run Rate in Under Seven Months

TIPRANKS
·
Sep 01

Z.AI's MaaS Annualized Revenue Hits $1.6 Billion, Surging 60% in a Single Month

Stock News
·
Aug 31

W-Stock Surges Over 8% Intraday, Huatai SecuritIEes Maintains 'Buy' Call

Deep News
·
Aug 31